(1) The total number of outstanding shares of the Company on 22 April 2025 mentioned in the transparency notification amounts to 52,867,073, each share giving right to one (1) vote (being 52,867,073 ...

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO ...

DelveInsight's "TRYVIO/JERAYGO Market Size, Forecast, and Market Insight Report" highlights the details around TRYVIO/JERAYGO ...

Protest will only grow in appeal and participation as we go deeper into the second term. You had to be there, at the Hands Off! protests last Saturday in Augusta and 20 other locations around ...

If you could choose to never know you had cancer, even if it meant a slightly raised risk of death decades down the line, would you do that? Many may choose to stay wilfully ignorant, especially ...

His rallies have also coincided with the resurgence of the Democratic “resistance” that existed during Trump’s first term. Democrats won a high-profile state Supreme Court race in Wisconsin ...

Researchers have found new compounds that could be used to treat a common breast cancer that can be resistant to hormone therapies. Published in the journal RSC Medicinal Chemistry, new research ...

The Euro to Pound (EUR/GBP) exchange rate has broken above 0.85 resistance and could target 0.87. A misleading headline suggesting that President Trump might postpone certain reciprocal tariffs ...

Despite boasting such a high dividend yield, this 12% dividend yield stock might be an excellent pick to build your recession-resistant portfolio. Most new investors get worried whenever market ...

As such, asked for a message to send to the president, as a number of other Axis of Resistance factions have shared with Newsweek in the past, Uli al-Baas declined, citing a gap between the White ...